TABLE 2.

Clinical Data from Patients 8–14 with PET-1 Scan Results Interpreted as PSMA-Negative

Patient	Indication	Gleason score, TNM	PSA value, dt PSA, and iPSA	PSMA tracer used in PET-1	No. of lesions interpreted as PSMA-positive with ⁸⁹Zr-PSMA-DFO in PET-2	Therapeutic consequence	Verification
8	BCR after RPE and S-RT	3 + 4, pT2 pN1	4.4, 5 mo, 24	⁶⁸Ga-PSMA-11	2 l.n. retroperitoneal PSMA-RADS 3A l.n. supraclav. left PSMA-RADS 3A miT0N1bM0	All 3 PSMA-positive l.n. treated with S-RT; start of temporary ADT	Decrease in PSA level to 0.17 ng/mL
9	BCR after RPE and S-RT	4 + 3, pT3 pN0	1.1, >12 mo, 14	¹⁸F-JK-PSMA-7	None PSMA-RADS 0 miT0N0M0	Watchful waiting	MRI also without finding
10	BCR after RPE. S-RT refused before PET	4 + 4, pT3a pN0	0.54, 10 mo, 7.7	¹⁸F-JK-PSMA-7	Prostate fossa right PSMA-RADS 4 miT2uN0M0	S-RT	Decrease in PSA level to 0.3 after S-RT
11	BCR after RPE and S-RT. ADT until 2 y before	4 + 5, pT3b pN0 R1	0.81, NA, 184	¹⁸F-JK-PSMA-7	None PSMA-RADS 0 miT0N0M0	Start with ADT at a PSA level of 1.71	MRI also without finding
12	BCR after RPE and S-RT	3 + 4, NA	1.78, 4 mo, 6.2	¹⁸F-JK-PSMA-7	None PSMA-RADS 0 miT0N0M0	Start with ADT for 1 y	MRI also without finding
13	BCR after RPE and S-RT	4 + 3, pT3b pN0	2.01, 1 mo, 8.5	⁶⁸Ga-PSMA-11	l.n. iliac right PSMA-RADS 3A miT0N1aM0	Start with ADT at a PSA level of 3.8	MRI with enlarged l.n. iliac right
14	BCR after RPE. S-RT not recommended before PET	3 + 4, pT2c pN0	0.7, 7 mo, NA	¹⁸F-JK-PSMA-7	Prostate fossa left PSMA-RADS 4 miT2uN0M0	S-RT	Decrease in PSA level to 0.09 after S-RT (6 wk after the end of S-RT)

Eight of the 14 patients showed PSMA-positive lesions with ⁸⁹Zr-PSMA-DFO. In 6 patients, the PSMA-negative interpretation from PET-1 was confirmed by the ⁸⁹Zr-PSMA-DFO PET-2. The location of each PSMA-positive lesion detected with ⁸⁹Zr-PSMA-DFO is described for each patient.
dtPSA = doubling time of PSA; iPSA = initial PSA; l.n. = lymph node; NA = not available; RPE = radical prostatectomy; RT = radiotherapy.